Literature DB >> 1325302

Potentiation of a weakly active ricin A chain immunotoxin recognizing the neural cell adhesion molecule.

E J Derbyshire1, R A Stahel, E J Wawrzynczak.   

Abstract

A ricin A chain immunotoxin, SEN36-ricin A chain, directed against the neural cell adhesion molecule (N-CAM) had no selective cytotoxic activity against three different small cell lung cancer (SCLC) cell lines in tissue culture despite expression of the target antigen on more than 98% of cells in each line detected by indirect immunofluorescence. Treatment of the SW2 SCLC cell line with suramin and interferons alpha and gamma increased the level of N-CAM expression only slightly and had no significant effect on the cytotoxic activity of the SEN36 immunotoxin. In the presence of the carboxylic ionophore monensin at a concentration of 0.1 microM, the toxicity of SEN36-ricin A chain to the SW2 cell line was enhanced by 12,000-fold. In contrast, lysosomotropic amines showed little or no potentiation of activity, suggesting that lysosomal degradation was not the major factor limiting the action of the anti-N-CAM immunotoxin. The findings of this study indicate that ricin A chain immunotoxins directed against N-CAM on SCLC are unlikely to have sufficient activity to be useful therapeutic agents in the absence of potentiating agents such as monensin, which can interfere with the normal intracellular pathways of antigen routing.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325302      PMCID: PMC1554476          DOI: 10.1111/j.1365-2249.1992.tb06958.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  Cytotoxic activity of ricin A chain immunotoxins recognising cluster 1, w4 and 5A antigens associated with human small cell lung cancer.

Authors:  E J Wawrzynczak; E J Derbyshire; R V Henry; G D Parnell; A Smith; R Waibel; R A Stahel
Journal:  Br J Cancer Suppl       Date:  1991-06

2.  An anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin.

Authors:  A A Hertler; D M Schlossman; M J Borowitz; H E Blythman; P Casellas; A E Frankel
Journal:  Int J Cancer       Date:  1989-02-15       Impact factor: 7.396

3.  Establishment and identification of small cell lung cancer cell lines having classic and variant features.

Authors:  D N Carney; A F Gazdar; G Bepler; J G Guccion; P J Marangos; T W Moody; M H Zweig; J D Minna
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

4.  Selective killing of human T-lymphotropic virus-I infected leukemic T-cells by monoclonal anti-interleukin 2 receptor antibody-ricin A chain conjugates: potentiation by ammonium chloride and monensin.

Authors:  M Krönke; E Schlick; T A Waldmann; E S Vitetta; W C Greene
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

5.  Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.

Authors:  T Griffin; V Raso
Journal:  Cancer Res       Date:  1991-08-15       Impact factor: 12.701

6.  Therapeutic application of radiolabeled monoclonal antibody UJ13A in children with disseminated neuroblastoma.

Authors:  L Lashford; D Jones; J Pritchard; I Gordon; F Breatnach; J T Kemshead
Journal:  NCI Monogr       Date:  1987

7.  Carrier protein-monensin conjugates: enhancement of immunotoxin cytotoxicity and potential in tumor treatment.

Authors:  M Colombatti; L Dell'Arciprete; R Chignola; G Tridente
Journal:  Cancer Res       Date:  1990-03-01       Impact factor: 12.701

8.  Two small cell lung cancer cell lines established from rigid bronchoscope biopsies.

Authors:  P E Postmus; L de Ley; A Y van der Veen; G Mesander; C H Buys; J D Elema
Journal:  Eur J Cancer Clin Oncol       Date:  1988-04

9.  Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant alpha-interferon.

Authors:  J W Pearson; E Hedrick; W E Fogler; R L Bull; D K Ferris; C W Riggs; R H Wiltrout; G Sivam; A C Morgan; E Groves
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 13.312

10.  Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen.

Authors:  E J Wawrzynczak; E J Derbyshire; R V Henry; G D Parnell; A Smith; R Waibel; R A Stahel
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

View more
  4 in total

Review 1.  Immunotoxins to human small-cell lung cancer.

Authors:  E J Wawrzynczak; E J Derbyshire
Journal:  Cell Biophys       Date:  1992 Aug-Dec

Review 2.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

3.  Immunotoxins recognising a new epitope on the neural cell adhesion molecule have potent cytotoxic effects against small cell lung cancer.

Authors:  U Zangemeister-Wittke; A R Collinson; B Frösch; R Waibel; T Schenker; R A Stahel
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 9.075

Review 4.  Augmenting the Efficacy of Immunotoxins and Other Targeted Protein Toxins by Endosomal Escape Enhancers.

Authors:  Hendrik Fuchs; Alexander Weng; Roger Gilabert-Oriol
Journal:  Toxins (Basel)       Date:  2016-07-01       Impact factor: 4.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.